Geir Frode Øy

  • PhD student; Siv.Ing./MSc
  • +47 22 78 17 87
 

Publications 2021

Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576

Publications 2020

Lavelle TJ, Alver TN, Heintz KM, Wernhoff P, Nygaard V, Nakken S, Øy GF, Bøe SL, Urbanucci A, Hovig E (2020)
Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes
Cancers (Basel), 12 (7)
DOI 10.3390/cancers12071719, PubMed 32605315

Publications 2019

Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2019)
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res, 33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681

Publications 2016

Alver TN, Lavelle TJ, Longva AS, Øy GF, Hovig E, Bøe SL (2016)
MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma
Oncotarget, 7 (34), 55128-55140
DOI 10.18632/oncotarget.10422, PubMed 27391157

Publications 2012

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA (2012)
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275

Publications 2010

Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500

Publications 2009

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847

Page visits: 4146